Collagen Solutions PLC Issue of Equity (4781J)
12 September 2016 - 4:00PM
UK Regulatory
TIDMCOS
RNS Number : 4781J
Collagen Solutions PLC
12 September 2016
12 September 2016
Collagen Solutions Plc
(the "Company" or "Collagen Solutions")
Issue of Equity and Director/PDMR Shareholding
Issue of Equity
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of medical grade collagen components for use in
regenerative medicine, medical devices and in-vitro diagnostics,
announces that it has issued, in aggregate, 8,217,475 new ordinary
shares in the Company ("Ordinary Shares") to certain vendors in
order to satisfy the initial tranche of the deferred consideration
share provisions in relation to the Collbio Limited ("Collbio")
acquisition, as announced on 10 December 2013, and the
ChondroMimetic assets acquisition, as announced on 14 September
2015.
Application has been made for the 8,217,475 new Ordinary Shares
to be admitted to trading on AIM ("Admission"), which is expected
to occur at 8.00 a.m. on or around 13 September 2016. The new
Ordinary Shares will rank pari passu with the existing Ordinary
Shares. Following Admission, and for the purposes of the Disclosure
and Transparency Rules, the Company's total issued share capital
will consist of 179,621,290 Ordinary Shares. Shareholders may use
this figure as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the issued share capital of the
Company.
Director/PDMR Shareholding
The Company announces that, pursuant to the issue of Ordinary
Shares in respect of the satisfaction of the initial tranche of
deferred consideration for the Collbio acquisition, Mr David Evans,
Chairman of the Company and a vendor of Collbio, was issued
2,685,437 new Ordinary Shares at a strike price of 12.5p per
Ordinary Share, and Dr Stewart White, Chief Scientific Officer and
a vendor of Collbio, was issued 1,553,592 Ordinary Shares at a
strike price of 12.5p per Ordinary Share. Following the issue of
new Ordinary Shares to Mr Evans and Dr White, Mr Evans' total
beneficial holding in the Company has increased to 18,874,167
Ordinary Shares, representing 10.5 per cent. of the issued ordinary
share capital of the Company following Admission, and Dr White's
total beneficial holding in the Company has increased to 5,017,919
Ordinary Shares, representing 2.8 per cent. of the issued ordinary
share capital of the Company following Admission respectively.
Enquiries:
Collagen Solutions Plc
Jamal Rushdy, CEO Mob: +1 612 405 7709
Gill Black, CFO Tel: 0141 648 9100
Panmure Gordon & Co (Nominated
Advisor and Broker)
Freddy Crossley, Duncan Monteith Tel: 020 7886 2500
(Corporate Finance)
Maisie Atkinson (Corporate Tel: 0207 886 2905
Sales)
Walbrook PR Ltd Tel: 020 7933 8780 or
collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Mike Wort Mob: 07900 608 002
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUKOVRNUAKRAR
(END) Dow Jones Newswires
September 12, 2016 02:00 ET (06:00 GMT)
Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024